共 50 条
Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents
被引:0
|作者:
Luo, Y
Rockow-Magnone, SK
Joseph, MK
Bradner, J
Butler, CC
Tahir, SK
Han, EKH
Ng, SC
Severin, JM
Gubbins, EJ
Reilly, RM
Rueter, A
Simmer, RL
Holzman, TF
Giranda, VL
机构:
[1] Abbott Labs, Canc Res Pharmaceut Prod Div, Dept 47S AP9A, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Canc Res Pharmaceut Prod Div, Dept 4N6 AP9, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Adv Technol Pharmaceut Prod Div, Dept 4MD AP10, Abbott Pk, IL 60064 USA
[4] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA
关键词:
G2;
abrogation;
Chkl;
UCN01;
staurosporine;
chemotherapy sensitization;
D O I:
暂无
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Background: Chkl is a checkpoint gene that is activated after DNA damage, It phosphorylates and inactivates Cdc25C at the late G2 phase. The inactivation of Cdc25C and consequently, the inactivation of Cdc2, are required for the G2 arrest induced by DNA damage. Methods: We treated 184B5 cell line and its E6 transformed cell lines with adriamycin in the presence of staurosporine or UCNO1 and examined induced a p53 and p21 response as well as a G1 arrest in 184B5 cells, but not in its E6 transformed cells. Staurosporine or UCNO1 abrogated the G2 arrest induced by adriamycin in both cell lines. In addition staurosporine or UCNO1 specifically sensitized p52 incompetent cells to adriamycin. Conclusion: G2/M checkpoint abrogators can potentially enhance the cytotoxic effect of conventional chemotherapeutic reagents specifically to tumor cells.
引用
收藏
页码:23 / 28
页数:6
相关论文